Operating cash flow turned negative in 2026Q2 and 2025Q4, with OCF-to-net-income ratios ranging from -0.61 to 13.35, and cumulative net portfolio purchases of roughly $22.5B against $19.0B in sales indicate float is being deployed rather than drawn upon.
Humana Inc. (HUM) cash flow statement — 30-year operating, investing & financing cash flows
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 | Dec'08 | Dec'07 | Dec'06 | Dec'05 | Dec'04 | Dec'03 | Dec'02 | Dec'01 | Dec'00 | Dec'99 | Dec'98 | Dec'97 | Dec'96 |
|---|
| Cash from Operations | 1.34B | 921M | 2.97B | 3.98B | 4.59B | 2.26B | 5.64B | 5.28B | 2.17B | 4.05B | 1.94B | 868M | 1.62B | 1.72B | 1.92B | 2.08B | 2.24B | 1.42B | 982.31M | 1.22B | 1.69B | 625.63M | 347.81M | 413.14M | 321.41M | 148.96M | 40M | 217M | 76M | 289M | 341M |
| Operating CF Growth % | 55.22% | -68.95% | -25.5% | -13.21% | 102.79% | -59.89% | 6.72% | 143.17% | -46.36% | 109.25% | 123.04% | -46.35% | -5.71% | -10.76% | -7.5% | -7.26% | 57.7% | 44.72% | -19.76% | -27.42% | 169.6% | 79.88% | -15.81% | 28.54% | 115.77% | 272.39% | -81.57% | 185.53% | -73.7% | -15.25% | 127.33% |
| Operating CF / Revenue % | 0.87% | 0.71% | 2.52% | 3.74% | 4.94% | 2.7% | 7.31% | 8.14% | 3.82% | 7.53% | 3.56% | 1.6% | 3.34% | 4.15% | 4.91% | 5.64% | 6.62% | 4.59% | 3.38% | 4.84% | 7.88% | 4.34% | 2.65% | 3.38% | 2.85% | 1.46% | 0.38% | 2.13% | 0.77% | 3.6% | 5.02% |
| Net Income | 1.25B | 1.2B | 1.21B | 2.49B | 2.8B | 2.93B | 3.37B | 2.71B | 1.68B | 2.45B | 614M | 1.28B | 1.15B | 1.23B | 1.22B | 1.42B | 1.1B | 1.04B | 647.15M | 833.68M | 487.42M | 308.48M | 280.01M | 228.93M | 142.75M | 117.17M | 90M | -394M | 129M | 173M | 12M |
| Depreciation & Amortization | 763M | 824M | 968M | 917M | 845M | 713M | 616M | 575M | 534M | 485M | 465M | 447M | 449M | 426M | 338M | 303M | 262.91M | 250.27M | 220.35M | 184.81M | 148.6M | 128.86M | 117.79M | 126.78M | 120.73M | 171.02M | 147M | 124M | 128M | 108M | 98M |
| Stock-Based Compensation | 231M | 241M | 207M | 175M | 216M | 180M | 181M | 163M | 137M | 157M | 115M | 109M | 98M | 92M | 82M | 67M | 62.95M | 65.87M | 55.37M | 42.13M | 32.56M | 11.32M | 4.02M | 6.34M | 0 | 0 | -30M | 0 | 0 | 0 | 0 |
| Deferred Taxes | 0 | 75M | -192M | -167M | -100M | 15M | 195M | 162M | 194M | 132M | -71M | -2M | -64M | 42M | -80M | 22M | -198.98M | -26.79M | -22M | -32.74M | 70.06M | -38.36M | 53.61M | 32.25M | 49.56M | 56.1M | 19M | 5M | 26M | 40M | -25M |
| Other Non-Cash Items | 1.19B | 375M | 615M | 486M | 290M | -1.02B | -863M | 14M | 792M | 141M | 66M | -346M | 22M | 71M | 46M | 50M | 57.53M | -19.48M | 97.52M | 37.91M | -1.41B | -400M | 27.93M | -48.56M | -124.33M | 146.45M | 26M | 472M | 17M | 6M | 72M |
| Working Capital Changes | -2.08B | -1.8B | 154M | 81M | 534M | -556M | 2.14B | 1.66B | -1.17B | 688M | 747M | -616M | -34M | -146M | 315M | 218M | 957.99M | 112.04M | -16.08M | 158.46M | 2.35B | 615.33M | -135.55M | 67.4M | 113.62M | -337.43M | -212M | 21M | -224M | -38M | 184M |
| Cash from Investing | -4.26B | 2.27B | -2.95B | -3.49B | -1.01B | -6.56B | -3.06B | -1.28B | -3.09B | -2.94B | -1.36B | 320M | -63M | -1.18B | -1.97B | -1.36B | -1.81B | -1.86B | -498.32M | -1.85B | -1.65B | -767.28M | -624.08M | -373.16M | -128.16M | -118.81M | -178M | 18M | 7M | -664M | -174M |
| Capital Expenditures | -592M | -546M | -575M | -1B | -1.14B | -1.34B | -964M | -736M | -612M | -526M | -527M | -523M | -528M | -437M | -410M | -336M | -222.3M | -185.45M | -261.57M | -239.24M | -193.15M | -165.85M | -114.1M | -101.27M | -112.14M | -114.97M | -135M | -89M | -104M | -73M | -72M |
| Acquisitions | -1.08B | -81M | -89M | -233M | 2.36B | -4.19B | -709M | 542M | -2.25B | -31M | -7M | 1.02B | 54M | -153M | -1.24B | -226M | -832.45M | -12.44M | -422.92M | -493.49M | -28.06M | -402.84M | -141.81M | 0 | 0 | -27.89M | 16M | -14M | 12M | -669M | -6M |
| Purchase of Investments | -8.31B | -6.44B | -8.19B | -7.55B | -6.05B | -7.2B | -9.13B | -6.36B | -4.69B | -6.26B | -6.57B | -6.74B | -2.88B | -3.26B | -3.22B | -3.68B | -4.59B | -7.2B | -5.68B | -3.49B | -4.27B | -3.72B | -4.11B | -4.57B | -2.57B | -1.87B | -1.21B | -781M | -1.04B | -608M | -440M |
| Sale/Maturity of Investments | 5.92B | 9.42B | 6.36B | 5.09B | 3.8B | 6.14B | 7.73B | 5.82B | 4.47B | 3.88B | 5.74B | 6.56B | 3.29B | 2.67B | 2.9B | 2.88B | 3.83B | 5.22B | 5B | 3.06B | 3.41B | 3.48B | 3.7B | 4.29B | 2.55B | 1.9B | 1.13B | 863M | 1.17B | 648M | 356M |
| Other Investing | -195M | -82M | -461M | 210M | 17M | 26M | 0 | -542M | -2.12B | 2M | -828M | 1M | 483M | -554M | -1.55B | 64M | 66K | 313.78M | 871.69M | -682.54M | -570.76M | 34.73M | 39.14M | 11.18M | 1.85M | 15.32M | 21M | 39M | -38M | 38M | -12M |
| Cash from Financing | 2.08B | -1.22B | -2.49B | -856M | -1.91B | 3.02B | -1.96B | -2.29B | -785M | -945M | 732M | -552M | -758M | -702M | -29M | -1.02B | -371.26M | 80.84M | -554.02M | 921.28M | 975.64M | 293.59M | -75.05M | 170.07M | -123.31M | -36.29M | -182M | -170M | 51M | 680M | -27M |
| Dividends Paid | -429M | -430M | -431M | -431M | -392M | -354M | -323M | -291M | -265M | -220M | -177M | -172M | -172M | -168M | -165M | -82M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -152M | -151M | -817M | -1.57B | -2.1B | -79M | -1.82B | -1.07B | -1.09B | -3.37B | -104M | -385M | -872M | -531M | -518M | -541M | -108.55M | -22.84M | -106.07M | -27.41M | -26.21M | -2.36M | -96.59M | -44.15M | -74.03M | -1.87M | -26.43M | 0 | 0 | 0 | 0 |
| Stock Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 61.64M | 48.73M | 38.23M | 27.62M | 27.68M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debt Issuance (Net) | -1000K | 1000K | 1000K | 1000K | -1000K | 1000K | 1000K | -1000K | 1000K | 1000K | 0 | 1000K | 1000K | 0 | 1000K | -1000K | -1000K | -1000K | 1000K | 1000K | 1000K | 1000K | -1000K | 1000K | -1000K | -1000K | -1000K | -1000K | 1000K | 1000K | -1000K |
| Other Financing | 2.49B | -1.06B | -1.46B | 725M | 1.97B | -310M | -890M | -511M | -595M | 1.89B | 1.01B | -260M | -878M | -3M | -375M | -291M | -227.26M | 203.76M | -595.81M | 623.07M | 109.14M | 0 | -8.65M | 28.23M | 6.6M | -6.64M | -2.69M | -13.99M | 35M | 14M | 1M |
| Net Change in Cash | -846M | 1.98B | -2.47B | -367M | 1.67B | -1.28B | 619M | 1.71B | -1.7B | 165M | 1.31B | 636M | 797M | -168M | -71M | -296M | 59.55M | -356.83M | -70.03M | 300.15M | 1.01B | 151.94M | -351.32M | 210.05M | 69.94M | -6.14M | -320M | 65M | 134M | 305M | 140M |
| Exchange Rate Effect | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash at Beginning | 6.89B | 2.22B | 4.69B | 5.06B | 3.39B | 4.67B | 4.05B | 2.34B | 4.04B | 3.88B | 2.57B | 1.94B | 1.14B | 1.31B | 1.38B | 1.67B | 1.61B | 1.97B | 2.04B | 1.74B | 732.02M | 580.08M | 931.4M | 721.36M | 651.42M | 657.56M | 978M | 913M | 779M | 322M | 182M |
| Cash at End | 6.93B | 4.2B | 2.22B | 4.69B | 5.06B | 3.39B | 4.67B | 4.05B | 2.34B | 4.04B | 3.88B | 2.57B | 1.94B | 1.14B | 1.31B | 1.38B | 1.67B | 1.61B | 1.97B | 2.04B | 1.74B | 732.02M | 580.08M | 931.4M | 721.36M | 651.42M | 658M | 978M | 913M | 627M | 322M |
| Free Cash Flow | 747M | 375M | 2.39B | 2.98B | 3.45B | 920M | 4.67B | 4.55B | 1.56B | 3.52B | 1.41B | 345M | 1.09B | 1.28B | 1.51B | 1.74B | 2.02B | 1.24B | 720.74M | 985.02M | 1.49B | 459.78M | 233.71M | 311.87M | 209.27M | 33.99M | -95M | 128M | -28M | 216M | 269M |
| FCF Growth % | -51.71% | -84.32% | -19.68% | -13.71% | 275% | -80.32% | 2.79% | 191.35% | -55.72% | 150.18% | 308.41% | -68.35% | -14.78% | -15.47% | -13.2% | -13.69% | 63.37% | 71.51% | -26.83% | -34.05% | 224.84% | 96.73% | -25.06% | 49.03% | 515.74% | 135.78% | -174.22% | 557.14% | -112.96% | -19.7% | 180.21% |
| FCF Margin % | 0.48% | 0.29% | 2.03% | 2.8% | 3.71% | 1.1% | 6.06% | 7% | 2.74% | 6.55% | 2.59% | 0.64% | 2.25% | 3.1% | 3.87% | 4.73% | 5.96% | 3.99% | 2.48% | 3.89% | 6.97% | 3.19% | 1.78% | 2.55% | 1.86% | 0.33% | -0.9% | 1.25% | -0.28% | 2.69% | 3.96% |
| FCF per Share | 6.13 | 3.1 | 19.78 | 23.92 | 27.15 | 7.11 | 35.15 | 33.76 | 11.28 | 24.21 | 9.34 | 2.28 | 6.99 | 8.04 | 9.26 | 10.39 | 11.89 | 7.31 | 4.27 | 5.8 | 8.89 | 2.79 | 1.44 | 1.92 | 1.22 | 0.2 | -0.57 | 0.76 | -0.17 | 1.3 | 1.63 |
Quick answers to the most common questions about buying HUM stock.
Humana Inc. (HUM) generated $921.0M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Humana Inc. (HUM) generated $375.0M in free cash flow in 2025. Free cash flow is the cash left over after capital expenditures, which can be used to pay dividends, repurchase shares, or pay down debt.
Humana Inc. (HUM) spent $546.0M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.
In 2025, Humana Inc. (HUM) returned $430.0M to shareholders via cash dividends and spent $151.0M on share repurchases. This shows the company's commitment to returning capital to its equity investors.
Key Metrics
Top Statement Risk
Volatile operating cash conversion
Metrics are mathematically derived from official filings.
Claims Outflows Drive Cash Volatility
Based on Humana's reported figures, quarterly claims and loss outflows rose from $25.0B in 2024Q2 to $36.3B in 2026Q3, a 45% increase that now dominates the company's cash profile and leaves little margin for timing mismatches between premium receipts and medical payments.
The steady climb in claims outflows tracks the membership and premium expansion visible in revenue, but the pace of growth in claims appears to have kept close to premium growth rather than pulling ahead of it. Because operating cash flow swung sharply between quarters, from $2.2B in 2026Q3 to negative $426M in 2026Q2, the timing of claim payments relative to premium collection appears to be the dominant short-term driver. Investors should monitor whether the seasonal year-end pattern, in which losses cluster in fourth quarters, continues to produce cash strain.
Float Generation Turns Erratic Quarterly
As reported in financial statements, operating cash flow ran positive in six of the ten quarters shown but turned negative in 2026Q2 and 2025Q4, with the OCF-to-net-income ratio ranging from negative 0.61 to 13.35, indicating that reported earnings are a poor guide to underlying cash generation.
The wide dispersion in OCF-to-net-income ratios suggests that the float generated by premiums held before claim payment is being absorbed unevenly across the year, rather than accumulating in a steady fashion. A quarter with 13x cash conversion against net income is better read as a timing effect on working balances than as evidence of durable earnings quality. Given the thin net margin of 0.9%, the company's underwriting cash generation appears to depend heavily on reserve and payable timing, which warrants further investigation through the reserve roll-forward.
Net Portfolio Buying Absorbs Operating Inflows
Based on Humana's reported figures, cumulative purchases of investments over the ten quarters total roughly $22.5B against sales of about $19.0B, meaning the company has been a net investor in its portfolio, deploying float into securities rather than drawing on it.
A net purchase pattern is consistent with a company that is growing its invested float as premiums expand, which is a reasonable use of cash in an insurance model. However, the quarters of heaviest buying, such as 2026Q3 and 2025Q3, coincide with periods of weaker operating cash, suggesting that portfolio deployment may be competing with liquidity needs. Investors should monitor whether this net buying persists if operating cash flow remains volatile.
Dividend Commitment Steady Against Thin Cushion
According to reported cash flow data, dividends paid held near $106M to $109M per quarter throughout the period, while buybacks were minimal and irregular, so the dividend remained a fixed outflow that was covered in most quarters but not in every one.
The stability of the dividend outflow indicates management is treating it as a committed distribution rather than a flexible lever. Coverage from operating cash flow was absent in 2026Q2 and 2025Q4, when cash generation turned negative, meaning the payout was funded from balance sheet resources in those periods. Given the modest 7.0% return on equity, the sustainability of the dividend depends on operating cash recovering consistently rather than in isolated quarters.
Earnings Quality Lags Reported Profit Signals
As reported in financial statements, net income was positive in most quarters yet turned negative in 2024Q4 and 2025Q4 at minus $693M and minus $796M, and these loss periods were not uniformly matched by negative operating cash, underscoring that accruals and reserve movements separate reported earnings from cash.
The divergence between net income and operating cash in several quarters suggests that non-cash items, including reserve changes and receivable timing, are materially shaping the reported figures. The fourth-quarter losses coinciding with year-end claims pressure may partly reflect estimation of incurred but unreported claims rather than cash shortfalls. Analysts should treat the latest beat as contingent on whether cash conversion normalizes in subsequent quarters.
What the Cash Statement Obscures
Based on Humana's reported figures, the cash flow statement does not separately isolate reserve development, risk-adjustment clawbacks, or reinsurance recoverables, so cash generation may look healthier or weaker than underlying claims obligations warrant.
Because the supplied cash data aggregates claims outflows without distinguishing prior-period reserve releases from current-year payments, a quarter of strong operating cash could partly reflect slower settlement of incurred but unreported claims rather than durable underwriting improvement. Investors should monitor prior-period development and reserve roll-forward disclosures, as these may reveal whether the reported cash conversion is sustainable. The absence of explicit disclosure on these items in the provided data means their magnitude cannot be verified here and should be treated as an open question.